Faculty profile

Maroie Barkati

Back to faculty

ProfessorDépartement de radiologie, radio-oncologie et médecine nucléaireUniversité de Montréal

Maroie Barkati

Professor

Département de radiologie, radio-oncologie et médecine nucléaire

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
10 publications in the last five years, latest in 2025.
Senior (last) author on 1 recent paper, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

159

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Université de Montréal profile.

Latest papers

Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial.
European urology · 2025
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial
The Lancet · 2024
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.
JAMA oncology · 2024

All 19 publications

19 publications.

Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial.

Niazi T, Nabid A, Malagon T, Tisseverasinghe S, Bettahar R, Dahmane R, Martin AG, Jolicoeur M, Yassa M, Barkati M, Igidbashian L, Bahoric B, Archambault R, Villeneuve H, Mohiuddin M

European urology202513 citations

DOI: 10.1016/j.eururo.2024.08.032 PMID: 39271420

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC

The Lancet202453 citationsOpen Access

DOI: 10.1016/s0140-6736(24)00548-8

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.

Buyyounouski MK, Pugh SL, Chen RC, Mann MJ, Kudchadker RJ, Konski AA, Mian OY, Michalski JM, Vigneault E, Valicenti RK, Barkati M, Lawton CAF, Potters L, Monitto DC, Kittel JA, Schroeder TM, Hannan R, Duncan CE, Rodgers JP, Feng F, Sandler HM

JAMA oncology202447 citationsOpen Access

DOI: 10.1001/jamaoncol.2023.7291 PMID: 38483412

Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial.

Niazi T, Nabid A, Malagon T, Bettahar R, Vincent L, Martin AG, Jolicoeur M, Yassa M, Barkati M, Igidbashian L, Bahoric B, Archambault R, Villeneuve H, Tsui JMG, Mohiuddin M

International journal of radiation oncology, biology, physics202418 citations

DOI: 10.1016/j.ijrobp.2023.05.014 PMID: 37224928

Pan-Canadian Survey of Radiation Oncology Professional Involvement in Global Oncology Initiatives in Low- and Middle-Income Countries.

Beckett M, Al Balushi M, Chan J, Iakovenko V, Roumeliotis M, Hanna T, Huang F, Barkati M, Rodin D, Bourque JM

JCO global oncology2024Open Access

DOI: 10.1200/go.23.00174 PMID: 38574301

Role of 18F-choline and 18F-fluorodeoxyglucose positron emission tomography in combination with magnetic resonance imaging in brachytherapy planning for locally advanced cervical cancer: A pilot study.

Rais F, Boudam K, Ménard C, Beauchemin MC, Oulmoudne N, Juneau D, Leblond A, Barkati M

Physics and imaging in radiation oncology2023Senior author

DOI: 10.1016/j.phro.2023.100467 PMID: 37497190

MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.

Ménard C, Navarro-Domenech I, Liu ZA, Joseph L, Barkati M, Berlin A, Delouya G, Taussky D, Beauchemin MC, Nicolas B, Kadoury S, Rink A, Raman S, Sundaramurthy A, Weersink R, Beliveau-Nadeau D, Helou J, Chung P

Frontiers in oncology202214 citationsOpen Access

DOI: 10.3389/fonc.2022.971344 PMID: 36091157

Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.

Frontiers in oncology2022Open Access

DOI: 10.3389/fonc.2022.1084708 PMID: 36465337

Prevalence and Risk Factors of QTc Prolongation in Prostate Cancer Patients Undergoing Brachytherapy.

Saad S, Delouya G, Lambert C, Barkati M, Dariane C, Laskine M, Taussky D

Cancer investigation2022

DOI: 10.1080/07357907.2022.2027435 PMID: 35000504

A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.

Charrois-Durand C, Saad F, Barkati M, Lattouf JB, Perrotte P, Karakiewicz PI, Soulières D, Blais N, Hamilou Z, Juneau D, Plouznikoff N, Taussky D, Delouya G

Canadian Urological Association journal = Journal de l'Association des urologues du Canada2022

DOI: 10.5489/cuaj.7591 PMID: 35099384

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Maroie Barkati

Research

Latest papers

Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial.

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.

Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial.

Pan-Canadian Survey of Radiation Oncology Professional Involvement in Global Oncology Initiatives in Low- and Middle-Income Countries.

Role of 18F-choline and 18F-fluorodeoxyglucose positron emission tomography in combination with magnetic resonance imaging in brachytherapy planning for locally advanced cervical cancer: A pilot study.

MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.

Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.

Prevalence and Risk Factors of QTc Prolongation in Prostate Cancer Patients Undergoing Brachytherapy.

A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.

Frequent collaborators

Guila Delouya

André-Guy Martin

Alejandro Berlin

Jean-Paul Bahary

Alexandra Rink

Peter Chung

Eric Vigneault

Talía Malagon

Samuel Kadoury

Robert Weersink

Jean-Marc Bourque

David Nguyen

Fred Saad

Michael Milosevic

Mira Keyes

Glenn Bauman

Paula Robson

Alan So

Michael Peacock

David Dawe

Wendy Parulekar

Michael Mckenzie

Stanley Liu

Scott Tyldesley

Juanita Crook

Douglas Loblaw

Maroie Barkati

Research

Latest papers

Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial.

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.

Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie G&#xe9;nito-Urinaire de Quebec Led Phase 3 Trial.

Pan-Canadian Survey of Radiation Oncology Professional Involvement in Global Oncology Initiatives in Low- and Middle-Income Countries.

Role of 18F-choline and 18F-fluorodeoxyglucose positron emission tomography in combination with magnetic resonance imaging in brachytherapy planning for locally advanced cervical cancer: A pilot study.

MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.

Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.

Prevalence and Risk Factors of QTc Prolongation in Prostate Cancer Patients Undergoing Brachytherapy.

A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.

Frequent collaborators

Guila Delouya

André-Guy Martin

Alejandro Berlin

Jean-Paul Bahary

Alexandra Rink

Peter Chung

Eric Vigneault

Talía Malagon

Samuel Kadoury

Robert Weersink

Jean-Marc Bourque

David Nguyen

Fred Saad

Michael Milosevic

Mira Keyes

Glenn Bauman

Paula Robson

Alan So

Michael Peacock

David Dawe

Wendy Parulekar

Michael Mckenzie

Stanley Liu

Scott Tyldesley

Juanita Crook

Douglas Loblaw

Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial.